南昌大学学报（医学版）
南昌大學學報（醫學版）
남창대학학보（의학판）
ACTA ACADEMIAE MEDICINAE JIANGXI
2014年
4期
51-53
,共3页
伍雪梅%姜红微%吴琳琳%徐瑾
伍雪梅%薑紅微%吳琳琳%徐瑾
오설매%강홍미%오림림%서근
卵巢癌%人附睾蛋白4%糖类抗原125%癌胚抗原
卵巢癌%人附睪蛋白4%糖類抗原125%癌胚抗原
란소암%인부고단백4%당류항원125%암배항원
ovarian cancer%human epididymis protein 4%carbohydrate antigen 125%carcinoembryonic antigen
目的：探讨肿瘤标志物[人附睾蛋白4（HE4）、糖类抗原125（CA125）及癌胚抗原（CEA）]联合检测在卵巢癌早期诊断中的应用价值。方法对47例卵巢癌患者（卵巢癌组，FIGO临床分期Ⅰ期6例、Ⅱ期12例、Ⅲ期14例、Ⅳ期15例）、63例良性卵巢疾病患者（良性病变组）及78例健康体检育龄妇女（对照组）进行 HE4、CA125及CEA检测，观察各组HE4、CA125、CEA血清水平变化及异常率；比较不同FIGO临床分期HE4、CA125、CEA血清水平的变化；对3种肿瘤标志物单独检测和联合检测对卵巢癌诊断的效果进行方法学评价。结果卵巢癌组的HE4、CA125及CEA血清水平及异常率均明显高于良性病变组及对照组（均P＜0．05），良性病变组与对照组比较差异均无统计学意义（均P＞0．05）；FIGO临床Ⅲ-Ⅳ期卵巢癌组 HE4、CA125及 CEA血清水平明显高于 FIGO临床Ⅰ-Ⅱ期卵巢癌组（均P＜0．001）。3种肿瘤标志物单独检测以 HE4及 CA1252项指标较好；3种肿瘤标志物联合检测对灵敏度、诊断符合率、约登指数及阴性预测值均有不同程度的提升。结论 HE4、CA125及 CEA联合检测对卵巢癌的防治有重要的临床意义。
目的：探討腫瘤標誌物[人附睪蛋白4（HE4）、糖類抗原125（CA125）及癌胚抗原（CEA）]聯閤檢測在卵巢癌早期診斷中的應用價值。方法對47例卵巢癌患者（卵巢癌組，FIGO臨床分期Ⅰ期6例、Ⅱ期12例、Ⅲ期14例、Ⅳ期15例）、63例良性卵巢疾病患者（良性病變組）及78例健康體檢育齡婦女（對照組）進行 HE4、CA125及CEA檢測，觀察各組HE4、CA125、CEA血清水平變化及異常率；比較不同FIGO臨床分期HE4、CA125、CEA血清水平的變化；對3種腫瘤標誌物單獨檢測和聯閤檢測對卵巢癌診斷的效果進行方法學評價。結果卵巢癌組的HE4、CA125及CEA血清水平及異常率均明顯高于良性病變組及對照組（均P＜0．05），良性病變組與對照組比較差異均無統計學意義（均P＞0．05）；FIGO臨床Ⅲ-Ⅳ期卵巢癌組 HE4、CA125及 CEA血清水平明顯高于 FIGO臨床Ⅰ-Ⅱ期卵巢癌組（均P＜0．001）。3種腫瘤標誌物單獨檢測以 HE4及 CA1252項指標較好；3種腫瘤標誌物聯閤檢測對靈敏度、診斷符閤率、約登指數及陰性預測值均有不同程度的提升。結論 HE4、CA125及 CEA聯閤檢測對卵巢癌的防治有重要的臨床意義。
목적：탐토종류표지물[인부고단백4（HE4）、당류항원125（CA125）급암배항원（CEA）]연합검측재란소암조기진단중적응용개치。방법대47례란소암환자（란소암조，FIGO림상분기Ⅰ기6례、Ⅱ기12례、Ⅲ기14례、Ⅳ기15례）、63례량성란소질병환자（량성병변조）급78례건강체검육령부녀（대조조）진행 HE4、CA125급CEA검측，관찰각조HE4、CA125、CEA혈청수평변화급이상솔；비교불동FIGO림상분기HE4、CA125、CEA혈청수평적변화；대3충종류표지물단독검측화연합검측대란소암진단적효과진행방법학평개。결과란소암조적HE4、CA125급CEA혈청수평급이상솔균명현고우량성병변조급대조조（균P＜0．05），량성병변조여대조조비교차이균무통계학의의（균P＞0．05）；FIGO림상Ⅲ-Ⅳ기란소암조 HE4、CA125급 CEA혈청수평명현고우 FIGO림상Ⅰ-Ⅱ기란소암조（균P＜0．001）。3충종류표지물단독검측이 HE4급 CA1252항지표교호；3충종류표지물연합검측대령민도、진단부합솔、약등지수급음성예측치균유불동정도적제승。결론 HE4、CA125급 CEA연합검측대란소암적방치유중요적림상의의。
Objective To explore the value of combined detection of tumor markers in early di-agnosis of ovarian cancer.Methods Serum levels of human epididymis protein 4 (HE4),carbohy-drate antigen 125 (CA 125)and carcinoembryonic antigen (CEA)were detected in 47 patients with ovarian cancer (ovarian cancer group,including FIGO Ⅰ in 6,FIGO Ⅱ in 12,FIGO Ⅲ in 14 and FIGOⅣ in 15),63 patients with benign ovarian diseases (benign lesion group)and 78 health-y subjects (control group).Serum HE4,CA125 and CEA levels and abnormal rates were com-pared among the three groups.Moreover,serum HE4,CA125 and CEA levels were compared a-mong different FIGO stages.The efficacies of separate and combined detection of the three tumor markers were evaluated in the three groups.Results Compared with ovarian cancer group,serum HE4,CA125 and CEA levels and abnormal rates significantly decreased in benign lesion group and control group(all P<0.05),but there were no significant differences between the two groups (all P>0.05).Compared with FIGO Ⅰ-Ⅱ,serum HE4,CA125 and CEA levels significantly in-creased in FIGO Ⅲ-Ⅳ(P<0.001).The indicators for HE4 or CA125 were better than those for CEA.Compared with separate detection,the sensitivity,diagnostic coincidence rate,Youden’s in-dex and negative predictive value were improved by combined detection of the three tumor mark-ers.Conclusion The combined detection of HE4,CA125 and CEA has an important clinical sig-nificance in the prevention and treatment of ovarian cancer.
